학술논문
Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study.
Document Type
Letter
Author
Source
Subject
*CHRONIC lymphocytic leukemia
*PROGRESSION-free survival
*LEUKEMIA treatment
*RITUXIMAB
*CHLORAMBUCIL
*
*
*
*
Language
ISSN
0887-6924
Abstract
The article discusses updated results of chronic lymphocytic leukemia (CLL)11 study that compared obinutuzumab plus chlorambucil (G-Clb), rituximab plus chlorambucil (R-Clb) and chlorambucil alone (Clb) on progression-free survival (PFS) and overall survival (OS), as of April 2014. Findings discussed include significantly longer PFS with G-Clb compared to R-Clb treatment, G-Clb having longer time to next antileukemic treatment than with R-Clb, and no significant OS benefit for G-Clb over R-Clb.